Characterization of 3 novel tau radiopharmaceuticals,11C-RO-963,11C-RO-643, and18F-RO-948, in healthy controls and in Alzheimer subjects

Dean Foster Wong, Robert A. Comley, Hiroto Kuwabara, Paul B Rosenberg, Susan M. Resnick, Susanne Ostrowitzki, Cristina Vozzi, Frank Boess, Esther Oh, Constantine G Lyketsos, Michael Honer, Luca Gobbi, Gregory Klein, Noble George, Lorena Gapasin, Kelly Kitzmiller, Josh Roberts, Jeff Sevigny, Ayon Nandi, James R BrasicChakradhar Mishra, Madhav Thambisetty, Abhay Mogekar, Anil Mathur, Marilyn Albert, Robert F Dannals, Edilio Borroni

Research output: Contribution to journalArticle

Abstract

11C-RO-963,11C-RO-643, and18F-RO-948 (previously referred to as11C-RO6924963,11C-RO6931643, and18F-RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data. Here we describe the first, to our knowledge, human evaluation of these novel radiotracers. Methods: Amyloid PET–positive Alzheimer disease (AD) subjects and younger controls each received 2 different tau tracers. Dynamic 90-min scans were obtained after bolus injection of11C-RO-963,11C-RO-643, or18F-RO-948. Arterial blood sampling was performed on 11 healthy controls and 11 AD subjects. Regions were defined on MR images, and PET data were quantified by plasma reference graphical analysis (for total distribution volume) and target cerebellum ratio (SUV ratios of 60- to 90-min frames). SUV ratio images were also analyzed voxelwise. Five older controls each underwent 2 scans with18F-RO-948 for evaluation of test–retest variability. Four AD subjects underwent a repeated18F-RO-948 scan 6–22 mo after the first scan. Six additional healthy controls (3 men and 3 women; age range, 41–67 y) each underwent 1 whole-body dosimetry scan with18F-RO-948. Results: In younger controls, SUVpeak was observed in the temporal lobe with values of approximately 3.0 for11C-RO-963, 1.5 for11C-RO-643, and 3.5 for18F-RO-948. Over all brain regions and subjects, the trend was for18F-RO-948 to have the highest SUVpeak, followed by11C-RO-963 and then11C-RO-643. Regional analysis of SUV ratio and total distribution volume for11C-RO-643 and18F-RO-948 clearly discriminated the AD group from the healthy control groups. Compartmental modeling confirmed that11C-RO-643 had lower brain entry than either11C-RO-963 or18F-RO-948 and that18F-RO-948 showed better contrast between (predicted) areas of high versus low tau accumulation. Thus, our subsequent analysis focused on18F-RO-948. Both voxelwise and region-based analysis of18F-RO-948 binding in healthy controls versus AD subjects revealed multiple areas where AD subjects significantly differed from healthy controls. Of 22 high-binding regions, 13 showed a significant group difference (after ANOVA, F(1,21) 5 45, P, 10-5). Voxelwise analysis also revealed a set of symmetric clusters where AD subjects had higher binding than healthy controls (threshold of P, 0.001, cluster size . 50). Conclusion:18F-RO-948 demonstrates characteristics superior to11C-RO-643 and11C-RO-963 for characterization of tau pathology in AD. Regional binding data and kinetic properties of18F-RO-948 compare favorably with other existing tau PET tracers.

Original languageEnglish (US)
Pages (from-to)1869-1876
Number of pages8
JournalJournal of Nuclear Medicine
Volume59
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Radiopharmaceuticals
Alzheimer Disease
Whole Body Imaging
Brain
Temporal Lobe
Amyloid
Cerebellum
Analysis of Variance
Pathology
Control Groups
Injections

Keywords

  • Alzheimer disease
  • Molecular imaging
  • Novel radiotracers
  • PET
  • Radiotracer development
  • Tau

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Characterization of 3 novel tau radiopharmaceuticals,11C-RO-963,11C-RO-643, and18F-RO-948, in healthy controls and in Alzheimer subjects. / Wong, Dean Foster; Comley, Robert A.; Kuwabara, Hiroto; Rosenberg, Paul B; Resnick, Susan M.; Ostrowitzki, Susanne; Vozzi, Cristina; Boess, Frank; Oh, Esther; Lyketsos, Constantine G; Honer, Michael; Gobbi, Luca; Klein, Gregory; George, Noble; Gapasin, Lorena; Kitzmiller, Kelly; Roberts, Josh; Sevigny, Jeff; Nandi, Ayon; Brasic, James R; Mishra, Chakradhar; Thambisetty, Madhav; Mogekar, Abhay; Mathur, Anil; Albert, Marilyn; Dannals, Robert F; Borroni, Edilio.

In: Journal of Nuclear Medicine, Vol. 59, No. 12, 01.12.2018, p. 1869-1876.

Research output: Contribution to journalArticle

Wong, DF, Comley, RA, Kuwabara, H, Rosenberg, PB, Resnick, SM, Ostrowitzki, S, Vozzi, C, Boess, F, Oh, E, Lyketsos, CG, Honer, M, Gobbi, L, Klein, G, George, N, Gapasin, L, Kitzmiller, K, Roberts, J, Sevigny, J, Nandi, A, Brasic, JR, Mishra, C, Thambisetty, M, Mogekar, A, Mathur, A, Albert, M, Dannals, RF & Borroni, E 2018, 'Characterization of 3 novel tau radiopharmaceuticals,11C-RO-963,11C-RO-643, and18F-RO-948, in healthy controls and in Alzheimer subjects', Journal of Nuclear Medicine, vol. 59, no. 12, pp. 1869-1876. https://doi.org/10.2967/jnumed.118.209916
Wong, Dean Foster ; Comley, Robert A. ; Kuwabara, Hiroto ; Rosenberg, Paul B ; Resnick, Susan M. ; Ostrowitzki, Susanne ; Vozzi, Cristina ; Boess, Frank ; Oh, Esther ; Lyketsos, Constantine G ; Honer, Michael ; Gobbi, Luca ; Klein, Gregory ; George, Noble ; Gapasin, Lorena ; Kitzmiller, Kelly ; Roberts, Josh ; Sevigny, Jeff ; Nandi, Ayon ; Brasic, James R ; Mishra, Chakradhar ; Thambisetty, Madhav ; Mogekar, Abhay ; Mathur, Anil ; Albert, Marilyn ; Dannals, Robert F ; Borroni, Edilio. / Characterization of 3 novel tau radiopharmaceuticals,11C-RO-963,11C-RO-643, and18F-RO-948, in healthy controls and in Alzheimer subjects. In: Journal of Nuclear Medicine. 2018 ; Vol. 59, No. 12. pp. 1869-1876.
@article{8435a9eaa6f141e380bebfea833e1a09,
title = "Characterization of 3 novel tau radiopharmaceuticals,11C-RO-963,11C-RO-643, and18F-RO-948, in healthy controls and in Alzheimer subjects",
abstract = "11C-RO-963,11C-RO-643, and18F-RO-948 (previously referred to as11C-RO6924963,11C-RO6931643, and18F-RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data. Here we describe the first, to our knowledge, human evaluation of these novel radiotracers. Methods: Amyloid PET–positive Alzheimer disease (AD) subjects and younger controls each received 2 different tau tracers. Dynamic 90-min scans were obtained after bolus injection of11C-RO-963,11C-RO-643, or18F-RO-948. Arterial blood sampling was performed on 11 healthy controls and 11 AD subjects. Regions were defined on MR images, and PET data were quantified by plasma reference graphical analysis (for total distribution volume) and target cerebellum ratio (SUV ratios of 60- to 90-min frames). SUV ratio images were also analyzed voxelwise. Five older controls each underwent 2 scans with18F-RO-948 for evaluation of test–retest variability. Four AD subjects underwent a repeated18F-RO-948 scan 6–22 mo after the first scan. Six additional healthy controls (3 men and 3 women; age range, 41–67 y) each underwent 1 whole-body dosimetry scan with18F-RO-948. Results: In younger controls, SUVpeak was observed in the temporal lobe with values of approximately 3.0 for11C-RO-963, 1.5 for11C-RO-643, and 3.5 for18F-RO-948. Over all brain regions and subjects, the trend was for18F-RO-948 to have the highest SUVpeak, followed by11C-RO-963 and then11C-RO-643. Regional analysis of SUV ratio and total distribution volume for11C-RO-643 and18F-RO-948 clearly discriminated the AD group from the healthy control groups. Compartmental modeling confirmed that11C-RO-643 had lower brain entry than either11C-RO-963 or18F-RO-948 and that18F-RO-948 showed better contrast between (predicted) areas of high versus low tau accumulation. Thus, our subsequent analysis focused on18F-RO-948. Both voxelwise and region-based analysis of18F-RO-948 binding in healthy controls versus AD subjects revealed multiple areas where AD subjects significantly differed from healthy controls. Of 22 high-binding regions, 13 showed a significant group difference (after ANOVA, F(1,21) 5 45, P, 10-5). Voxelwise analysis also revealed a set of symmetric clusters where AD subjects had higher binding than healthy controls (threshold of P, 0.001, cluster size . 50). Conclusion:18F-RO-948 demonstrates characteristics superior to11C-RO-643 and11C-RO-963 for characterization of tau pathology in AD. Regional binding data and kinetic properties of18F-RO-948 compare favorably with other existing tau PET tracers.",
keywords = "Alzheimer disease, Molecular imaging, Novel radiotracers, PET, Radiotracer development, Tau",
author = "Wong, {Dean Foster} and Comley, {Robert A.} and Hiroto Kuwabara and Rosenberg, {Paul B} and Resnick, {Susan M.} and Susanne Ostrowitzki and Cristina Vozzi and Frank Boess and Esther Oh and Lyketsos, {Constantine G} and Michael Honer and Luca Gobbi and Gregory Klein and Noble George and Lorena Gapasin and Kelly Kitzmiller and Josh Roberts and Jeff Sevigny and Ayon Nandi and Brasic, {James R} and Chakradhar Mishra and Madhav Thambisetty and Abhay Mogekar and Anil Mathur and Marilyn Albert and Dannals, {Robert F} and Edilio Borroni",
year = "2018",
month = "12",
day = "1",
doi = "10.2967/jnumed.118.209916",
language = "English (US)",
volume = "59",
pages = "1869--1876",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "12",

}

TY - JOUR

T1 - Characterization of 3 novel tau radiopharmaceuticals,11C-RO-963,11C-RO-643, and18F-RO-948, in healthy controls and in Alzheimer subjects

AU - Wong, Dean Foster

AU - Comley, Robert A.

AU - Kuwabara, Hiroto

AU - Rosenberg, Paul B

AU - Resnick, Susan M.

AU - Ostrowitzki, Susanne

AU - Vozzi, Cristina

AU - Boess, Frank

AU - Oh, Esther

AU - Lyketsos, Constantine G

AU - Honer, Michael

AU - Gobbi, Luca

AU - Klein, Gregory

AU - George, Noble

AU - Gapasin, Lorena

AU - Kitzmiller, Kelly

AU - Roberts, Josh

AU - Sevigny, Jeff

AU - Nandi, Ayon

AU - Brasic, James R

AU - Mishra, Chakradhar

AU - Thambisetty, Madhav

AU - Mogekar, Abhay

AU - Mathur, Anil

AU - Albert, Marilyn

AU - Dannals, Robert F

AU - Borroni, Edilio

PY - 2018/12/1

Y1 - 2018/12/1

N2 - 11C-RO-963,11C-RO-643, and18F-RO-948 (previously referred to as11C-RO6924963,11C-RO6931643, and18F-RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data. Here we describe the first, to our knowledge, human evaluation of these novel radiotracers. Methods: Amyloid PET–positive Alzheimer disease (AD) subjects and younger controls each received 2 different tau tracers. Dynamic 90-min scans were obtained after bolus injection of11C-RO-963,11C-RO-643, or18F-RO-948. Arterial blood sampling was performed on 11 healthy controls and 11 AD subjects. Regions were defined on MR images, and PET data were quantified by plasma reference graphical analysis (for total distribution volume) and target cerebellum ratio (SUV ratios of 60- to 90-min frames). SUV ratio images were also analyzed voxelwise. Five older controls each underwent 2 scans with18F-RO-948 for evaluation of test–retest variability. Four AD subjects underwent a repeated18F-RO-948 scan 6–22 mo after the first scan. Six additional healthy controls (3 men and 3 women; age range, 41–67 y) each underwent 1 whole-body dosimetry scan with18F-RO-948. Results: In younger controls, SUVpeak was observed in the temporal lobe with values of approximately 3.0 for11C-RO-963, 1.5 for11C-RO-643, and 3.5 for18F-RO-948. Over all brain regions and subjects, the trend was for18F-RO-948 to have the highest SUVpeak, followed by11C-RO-963 and then11C-RO-643. Regional analysis of SUV ratio and total distribution volume for11C-RO-643 and18F-RO-948 clearly discriminated the AD group from the healthy control groups. Compartmental modeling confirmed that11C-RO-643 had lower brain entry than either11C-RO-963 or18F-RO-948 and that18F-RO-948 showed better contrast between (predicted) areas of high versus low tau accumulation. Thus, our subsequent analysis focused on18F-RO-948. Both voxelwise and region-based analysis of18F-RO-948 binding in healthy controls versus AD subjects revealed multiple areas where AD subjects significantly differed from healthy controls. Of 22 high-binding regions, 13 showed a significant group difference (after ANOVA, F(1,21) 5 45, P, 10-5). Voxelwise analysis also revealed a set of symmetric clusters where AD subjects had higher binding than healthy controls (threshold of P, 0.001, cluster size . 50). Conclusion:18F-RO-948 demonstrates characteristics superior to11C-RO-643 and11C-RO-963 for characterization of tau pathology in AD. Regional binding data and kinetic properties of18F-RO-948 compare favorably with other existing tau PET tracers.

AB - 11C-RO-963,11C-RO-643, and18F-RO-948 (previously referred to as11C-RO6924963,11C-RO6931643, and18F-RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data. Here we describe the first, to our knowledge, human evaluation of these novel radiotracers. Methods: Amyloid PET–positive Alzheimer disease (AD) subjects and younger controls each received 2 different tau tracers. Dynamic 90-min scans were obtained after bolus injection of11C-RO-963,11C-RO-643, or18F-RO-948. Arterial blood sampling was performed on 11 healthy controls and 11 AD subjects. Regions were defined on MR images, and PET data were quantified by plasma reference graphical analysis (for total distribution volume) and target cerebellum ratio (SUV ratios of 60- to 90-min frames). SUV ratio images were also analyzed voxelwise. Five older controls each underwent 2 scans with18F-RO-948 for evaluation of test–retest variability. Four AD subjects underwent a repeated18F-RO-948 scan 6–22 mo after the first scan. Six additional healthy controls (3 men and 3 women; age range, 41–67 y) each underwent 1 whole-body dosimetry scan with18F-RO-948. Results: In younger controls, SUVpeak was observed in the temporal lobe with values of approximately 3.0 for11C-RO-963, 1.5 for11C-RO-643, and 3.5 for18F-RO-948. Over all brain regions and subjects, the trend was for18F-RO-948 to have the highest SUVpeak, followed by11C-RO-963 and then11C-RO-643. Regional analysis of SUV ratio and total distribution volume for11C-RO-643 and18F-RO-948 clearly discriminated the AD group from the healthy control groups. Compartmental modeling confirmed that11C-RO-643 had lower brain entry than either11C-RO-963 or18F-RO-948 and that18F-RO-948 showed better contrast between (predicted) areas of high versus low tau accumulation. Thus, our subsequent analysis focused on18F-RO-948. Both voxelwise and region-based analysis of18F-RO-948 binding in healthy controls versus AD subjects revealed multiple areas where AD subjects significantly differed from healthy controls. Of 22 high-binding regions, 13 showed a significant group difference (after ANOVA, F(1,21) 5 45, P, 10-5). Voxelwise analysis also revealed a set of symmetric clusters where AD subjects had higher binding than healthy controls (threshold of P, 0.001, cluster size . 50). Conclusion:18F-RO-948 demonstrates characteristics superior to11C-RO-643 and11C-RO-963 for characterization of tau pathology in AD. Regional binding data and kinetic properties of18F-RO-948 compare favorably with other existing tau PET tracers.

KW - Alzheimer disease

KW - Molecular imaging

KW - Novel radiotracers

KW - PET

KW - Radiotracer development

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=85057626798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057626798&partnerID=8YFLogxK

U2 - 10.2967/jnumed.118.209916

DO - 10.2967/jnumed.118.209916

M3 - Article

C2 - 29728519

AN - SCOPUS:85057626798

VL - 59

SP - 1869

EP - 1876

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 12

ER -